The Bugatti Destrier is not merely an outrageously rare hypercar. It is a high-margin demonstration of what happens when engineering scarcity, collector demand, and bespoke craftsmanship are allowed to share the same garage—without first consulting a committee that owns sensible shoes. For…
Sable Offshore Corp. (NYSE: SOC) is shaping up as one of the more unusual—and potentially compelling—U.S. energy turnaround stories: a concentrated, infrastructure-backed restart of offshore California oil production just as domestic supply security has returned to the policy conversation. The latest catalyst…
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…
“Sovereign AI” is quickly moving from buzzword to policy priority as governments realize that renting intelligence from hyperscale clouds is not a long‑term strategy when data, defense, healthcare, and financial systems are at stake. Platforms like Seven Boson Group Ltd. are positioning…
Wall Street is finally admitting what Eric Schmidt just said out loud: if AI is going to be powerful enough to “pull the plug” on us, it had better be built in a way that lets nations and investors keep their hand…
